Join the Oncology Voice Network. Join for Free
How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer
MSL Consultant KOL relationships strategic objectives stakeholder mapping Pharma practices

How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer


Share This Article


Summary

My guest today is Aoife O Dwyer, Founder of MSL Consultant, and we discuss how to leverage KOL relationships to achieve strategic objectives.

In this episode:

  • What made Aoife decide to become an MSL Consultant and what she likes best about her role
  • Aoife’s advice to MSLs who want to demonstrate their value to their company
  • Most important things for people to remember in KOL identifications and stakeholder mapping
  • Tips on getting a KOL meeting
  • How can an MSL deliver value in a KOL meeting
  • How can an MSL plan for a KOL meeting
  • How has COVID affected an MSL’s ability to provide value and what advice Aoife can give to MSLs in handling this crisis
  • What skills are now mandatory for MSLs during and after the COVID crisis to provide value to their KOLs and to their organization
  • How Aoife expects Pharma to change practices as a result of Covid-19
  • Advice to MSLs to help aid in their success

Click for Source
MSL Consultant, KOL relationships, strategic objectives, stakeholder mapping, Pharma practices

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Build Scientific Credibility for Continuous Career Development
Partner Avatar MSL Talk: Tom Caravela, Ike Ogbaa

How to Build Scientific Credibility for Continuous Career Development

Podcast
What I DO….How I BUILD Relationships
Partner Avatar MSL Talk: Tom Caravela, Bernadett Mamone

What I DO….How I BUILD Relationships

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN